Napo Pharmaceuticals announced that the late-breaker abstract Napo submitted to MASCC on additional significant results in adult breast cancer patients from the OnTarget study has been accepted for ...

Jaguar Health’s (JAGX) Napo Pharmaceuticals announced that the late-breaker abstract Napo submitted to MASCC on additional significant results in adult breast cancer patients from the OnTarget ...

The growing morbidity, mortality, and health care costs related to heart failure (HF) underscore the urgent need to prioritize its primary prevention. Whereas a risk-based approach for HF prevention ...

This page features the latest news about the Jaguar Health share. Proof-of-Concept Data for Rare Disease Indications MVID and SBS-IF for Jaguar Health’s Crofelemer to be Presented at April 2025 ELITE ...